Salute e Benessere

Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting

Oslo, January 8, 2025:In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9, 2025, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy-based voting rights without voting instructions for 8,652,094 shares, representing 25.15% of the total voting rights in the company.The proxies are only valid for the Extraordinary General Meeting on January 9, 2025. This information is subject of the disclosure requirements pursuant to...

Helsinn Group and ESTEVE sign a partnership agreement renewal to commercialize…

Helsinn Group and ESTEVE sign a partnership agreement renewal to commercialize AKYNZEO ®and ALOXI ®in GermanyLugano, Switzerland – January 8, 2025– Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, and ESTEVE, an international specialty pharma company with a focus on highly specialized treatments that address significant unmet...

Alma Harmony Wins European Product Design Award in Healthcare Category

Alma Harmony, the latest innovation from Alma Lasers, builds on a 20-year legacy of excellence to redefine in-office aesthetic treatments. This state-of-the-art platform seamlessly integrates five cutting-edge technologies, providing a comprehensive solution for a wide range of indications and skin types. Alma Harmony, the latest innovation from Alma Lasers, builds on a 20-year legacy of excellence to redefine in-office aesthetic treatments. This state-of-the-art platform seamlessly…

Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive…

AT-7687 offers a new mechanism of action, to set a new standard in obesity management AT-7687 offers a new mechanism of action, to set a new standard in obesity management COPENHAGEN, Denmark , Jan. 8, 2025 /PRNewswire/ -- Antag Therapeutics ("Antag" or "the company"), a biopharmaceutical company pioneering novel treatments for obesity, today announced the appointment ofJoerg Moeller, MD, PhD, as Chief Executive Officer, effective immediately. Dr. Moeller succeeds Antag's...

Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to…

Dr Schuurman also played a key role in the development of antibody platform technologies while at Genmab, such as DuoBody® and HexaBody®, and rose to become Senior Vice President, Head of Antibody Research and Development. A renowned speaker at scientific conferences, Dr Schuurman is currently President of The Antibody Society, a highly regarded non-profit supporting antibody-related research and development. Dr Schuurman also played a key role in the development of antibody platform...

The Galien Foundation Announces the Prix Galien UK 2025 Awards Committee

"I am greatly looking forward to continuing my role as Chair of the Prix Galien UK Awards Committee, alongside some of the greatest minds at the forefront of global healthcare," said Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine at the University of Liverpool and the NHS Chair of Pharmacogenetics. "The collaborative ethos of this committee reflects The Galien Foundation's mission to serve as a vehicle for the open exchange of ideas that drive science and new…

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into…

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactionsGalapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy...

Basilea provides portfolio update and outlook

Allschwil, Switzerland, January 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on the progress of its Research & Development portfolio in 2024 and upcoming milestones.David Veitch, Chief Executive Officer, said: “We have achieved several significant milestones in 2024. We partnered with a highly committed, focused and capable...

Roche purchases shares in tender offer for Poseida Therapeutics, Inc.

Citibank, N.A., the depositary for the tender offer, advised Roche that a total of approximately 64,991,586 shares of Poseida's common stock were validly tendered and not validly withdrawn in the tender offer (excluding shares tendered by notice of guaranteed delivery for which certificates have not yet been “received”), which represent approximately 66.11% of the total number of shares of Poseida's common stock outstanding.Later today, Roche intends to complete the acquisition of Poseida...

Addex to Present at the 2025 Swiss Equities Baader Conference

Geneva, Switzerland, January 8, 2025-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at theSwiss Equities Baader Conferencebeing held in Bad Ragaz, Switzerland, January 08-10, 2025.In his presentation, Dr Lütjens will provide a corporate update and discuss...

Dr. Eyal S. Ron Joins AmacaThera Board of Directors to Drive Strategic Growth…

"Dr. Ron combines unmatched scientific expertise combined with a track record of effective business leadership, making him a key driver of innovation and growth at AmacaThera." said Dr. Mike Cooke, CEO of AmacaThera. "His exceptional ability to foster innovation, establish strategic partnerships, lead business development initiatives, and provide strong governance will be instrumental in advancing the Company's strategic goals and accelerating the development of groundbreaking…

uniQure Announces Proposed Public Offering

Leerink Partners is acting as the bookrunning manager for the proposed offering.The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC's website athttp://www.sec...

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43 rdAnnual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco. A live webcast of the presentation will be accessible on the Investors page of the Company's website atwww.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be archived for...

World's First and Smartest 3-in-1 Battery Charger, Ostation X, Debuts at CES…

The Ostation X was inspired by the need for sustainable battery solutions, addressing billions of discarded single-use batteries in the world that contribute to pollution. Olight's mission was to create a product that encourages the adoption of rechargeable batteries by making them more convenient, reliable, and easy to use. The Ostation X fulfills this mission and helps to reduce waste and promote long-term cost savings. The Ostation X was inspired by the need for sustainable battery...

Global Market for Cell and Gene Therapy Tools and Reagents Projected to Grow at…

The report breaks down the global market for cell and gene therapy (CGT) tools and reagents by product type, disease or application, end user, and region. Product types include gene vectors, proteins, antibodies, small molecules, bioreactors, and assays. The report covers diseases like cancer and rare diseases, and end users such as pharmaceutical companies, biotech firms, research institutes, and clinical labs. It also provides market estimates from 2023 to 2029. The report breaks down the...

Ipsen - December 2024 - Monthly information relative to the total number of…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1) 31 December 202483,814,526Gross...

SAFE GROUP - 16th Journées Thérapeutiques Interventionnelles Vertébrales et…

16th Journées Thérapeutiques Interventionnelles Vertébrales et Ostéo-Articulaires: presentation of Professor Maestretti's clinical results on the Sycamore deviceFleurieux-sur-l'Arbresle - France – January 7, 2025 at 6pm.Safe announces that Professor Gianluca Maestretti, Head of Orthopaedics at the Freiburg Hospital, will present his clinical results on the Sycamore device at the 16th Journées Thérapeutiques Interventionnelles Vertébrales et Ostéo-Articulaires, to be held in Nice on...

Ipsen - Half year statement - 2024 12 31

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHFBoulogne-Billancourt (France), January 7 th, 2025 –Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2024, the following resources were included to the dedicated liquidity account: 24,701 shares€2,635,980.25 It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account: 12,751 shares...

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS) and indirect treatment comparison to the International Guillain-Barré Syndrome Outcome Study (IGOS) demonstrating the potential of imlifidase, the Company's first-generation IgG cleaving molecule, to address a significant unmet need in GBS. Additionally, the GOOD-IDES-02 (Phase 3 trial in anti-GBM) completed enrolment and positive results from the NICE-01 Phase 1 trial and…

Nailing Systems Market to Hit US$553.2 Billion by 2029 with 5.3% CAGR |…

Browse in-depth TOC on 'Nailing Systems Market' Browse in-depth TOC on 'Nailing Systems Market' 312 - Tables 48 - Figures 292 - Pages The nailing systems market is divided into femoral fracture, tibial fracture, metaphyseal fracture, humeral fracture, hip fracture, and other indications based on indication. In the year 2023, the nailing systems market was dominated by the tibial fracture. The large share of the tibial fracture is attributed to rising prevalence of road accidents...

Renovaro Issues Shareholder Letter and Provides Corporate Update

Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan.07, 2025(GLOBE NEWSWIRE) --Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein.Dear Shareholders,As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our...

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan.07, 2025(GLOBE NEWSWIRE) --Renovaro Inc. (NASDAQ: RENB),a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh.Nathen Fuentes comes to Renovaro as...

Cyclarity Therapeutics Secures Approval for First-in-Human Clinical Trial

Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial.The trial will be conducted at CMAX, one of Australia's leading clinical research centers, in partnership with Monash University. This effort will be led by Dr. Stephen Nicholls of the Victorian Heart Institute (VHI), a distinguished leader in cardiovascular medicine. In addition to a traditional SAD/MAD phase 1 trial, the authorization includes an allowance to enroll 12 patients...

Ori Biotech Announces First Customer Deliveries of IRO to Leading CDMOs and…

Six months after its unveiling, the IRO platform is now being deployed to customers Oribiotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, announces the first customer deliveries of the new IRO ®platform, specifically designed to help address the current challenges in CGT manufacturing. In December 2024, four IRO instruments were delivered to multiple leading contract development and manufacturing organizations (CDMOs) and a prominent global...

Altri Comunicati